Sarepta Therapeutics, Inc. (SRPT) vs Trevi Therapeutics, Inc. (TRVI)
A side-by-side comparison of Sarepta Therapeutics, Inc. and Trevi Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
SRPT
Sarepta Therapeutics, Inc.
$17.31HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TRVI
Trevi Therapeutics, Inc.
$13.18HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — SRPT vs TRVI
growth of $100 · dividends reinvested · last 7ySRPT -84.9% (-23.6%/yr)TRVI +73.9% (+8.2%/yr)TRVI compounded faster over this window
Log scale — wide-divergence pair
SRPT TRVI
SRPT vs TRVI: by the numbers
- •TRVI is the larger company ($1.87B vs $1.83B market cap).
- •Both run net losses; TRVI's is the smaller (0.00% vs -6.93% net margin).
Metrics side by side
Valuation
| Metric | SRPT | TRVI |
|---|---|---|
| Forward P/E | 5.38 | N/A |
| P/S ratio | 0.93 | N/A |
| P/B ratio | 1.20 | 5.82 |
Profitability
| Metric | SRPT | TRVI |
|---|---|---|
| Gross margin | 58.56% | 0.00% |
| Operating margin | -29.92% | 0.00% |
| Net margin | -6.93% | 0.00% |
| ROE | -8.95% | -15.90% |
| ROIC | -5.33% | -18.51% |
Growth (annualized)
| Metric | SRPT | TRVI |
|---|---|---|
| Revenue CAGR (5Y) | 26.90% | N/A |
| Total return CAGR (5Y) | -28.74% | 61.74% |
Frequently asked
- How have SRPT and TRVI total returns compared?
- Over the past 5 years, SRPT delivered -28.74% and TRVI delivered 61.74% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Sarepta Therapeutics ROETrevi Therapeutics ROESarepta Therapeutics operating marginTrevi Therapeutics operating marginSarepta Therapeutics revenue growthTrevi Therapeutics revenue growthSarepta Therapeutics free cash flowTrevi Therapeutics free cash flow
Sarepta Therapeutics & Trevi Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.